CD86 and neoplasm: The AMPK pathway counteracts mTOR signaling [90], with AMPK activation in tumor-associated DCs typically inducing tolerogenic properties characterized by improved mitochondrial function, increased FAO and OXPHOS, and diminished CD80/CD86 expression [3, 91, 92].